This Phase 2a clinical trial is designed to evaluate the immunogenicity and the safety of one
administration of OVX836 influenza vaccine at different dose levels (180g, 300g and 480g)
in order to assess the dose response of the OVX836 influenza vaccine.
This trial is a Phase 2a, randomized, double-blind, controlled study in 138 adult subjects to
compare the immunogenicity and the safety of OVX836 influenza vaccine at two dose levels
(300g and 480g) to lower dose level (180g) and to placebo.
One single dose of OVX836 influenza vaccine (180g or 300g or 480g) or of placebo will be
administered intramuscularly in healthy subjects aged 18-55 years.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.